SECISBP2L and B-cell chronic lymphocytic leukemia: MLR-high CLL patients showed a decrease in the percentage of pro-inflammatory nonclassical monocytes (SLAN+) and an increase in the proportion of intermediate monocytes (SLAN−) with potential anti-inflammatory capacity.